Cytek Biosciences, Inc. $CTKB Shares Bought by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio increased its stake in Cytek Biosciences, Inc. (NASDAQ:CTKB) by 448.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,906 shares of the company’s stock after purchasing an additional 56,333 shares during the quarter. Public Employees Retirement System of Ohio owned about 0.05% of Cytek Biosciences worth $234,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC acquired a new stake in Cytek Biosciences in the first quarter worth about $63,000. New York State Teachers Retirement System lifted its holdings in Cytek Biosciences by 6.8% in the first quarter. New York State Teachers Retirement System now owns 48,463 shares of the company’s stock worth $194,000 after purchasing an additional 3,100 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in Cytek Biosciences in the first quarter worth about $2,841,000. Principal Financial Group Inc. lifted its holdings in Cytek Biosciences by 2.7% in the first quarter. Principal Financial Group Inc. now owns 520,743 shares of the company’s stock worth $2,088,000 after purchasing an additional 13,818 shares during the period. Finally, Nuveen LLC acquired a new stake in Cytek Biosciences in the first quarter worth about $1,223,000. Institutional investors and hedge funds own 69.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytek Biosciences in a report on Saturday, September 27th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.60.

Cytek Biosciences Trading Up 1.3%

NASDAQ CTKB opened at $4.02 on Tuesday. The stock’s 50-day moving average price is $3.89 and its two-hundred day moving average price is $3.57. The company has a market cap of $511.42 million, a PE ratio of -80.40 and a beta of 1.31. Cytek Biosciences, Inc. has a 1 year low of $2.37 and a 1 year high of $7.63.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.